Amicus Therapeutics Inc. (FOLD)
NASDAQ: FOLD
· Real-Time Price · USD
5.74
-0.19 (-3.20%)
At close: Jun 30, 2025, 3:00 PM
Revenue by Geography
| Period Ending | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|
| Non-Us Revenue | 282.03M | 252.42M | 213.29M | 210.13M | 180.84M | 129.76M |
| Non-Us Revenue Growth | +11.73% | +18.35% | +1.50% | +16.19% | +39.37% | n/a |
| United States Revenue | 176.02M | 146.94M | 115.95M | 95.39M | 80.05M | 52.48M |
| United States Revenue Growth | +19.80% | +26.73% | +21.55% | +19.17% | +52.53% | n/a |
Operating Expense Breakdown
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 | Dec 31, 2017 | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 | Sep 30, 2016 | Jun 30, 2016 | Mar 31, 2016 | Dec 31, 2015 | Sep 30, 2015 | Jun 30, 2015 | Mar 31, 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selling, General, and Administrative Revenue | 91.83M | 86.67M | 75.11M | 73.58M | 88.03M | 70.24M | 65.65M | 65.42M | 73.96M | 54.27M | 47.27M | 53.38M | 58.12M | 57.6M | 46.11M | 42.28M | 46.73M | 43.69M | 37.85M | 34.66M | 40.22M | 43.3M | 39.68M | 42.58M | 44.3M | 38.77M | 31.87M | 29.17M | 27.4M | 28.58M | 21.65M | 19.31M | 19.13M | 18.68M | 17.47M | 19.3M | 15.7M | 17.19M | 15.37M | 8.28M | 6.43M |
| Selling, General, and Administrative Revenue Growth | +5.95% | +15.39% | +2.08% | -16.42% | +25.33% | +6.99% | +0.35% | -11.54% | +36.27% | +14.81% | -11.44% | -8.15% | +0.89% | +24.93% | +9.06% | -9.52% | +6.96% | +15.42% | +9.21% | -13.82% | -7.12% | +9.12% | -6.81% | -3.89% | +14.29% | +21.65% | +9.24% | +6.48% | -4.15% | +32.03% | +12.10% | +0.94% | +2.41% | +6.94% | -9.49% | +22.92% | -8.67% | +11.84% | +85.70% | +28.80% | n/a |
| Research and Development Revenue | 27.84M | 30.19M | 26.16M | 24.68M | 28.33M | 35.03M | 40.7M | 35.15M | 41.5M | 63.87M | 52.97M | 78.32M | 81.52M | 85.6M | 59.33M | 63M | 64.12M | 79.29M | 70.42M | 69.61M | 89.12M | 91.91M | 58.89M | 70.98M | 64.59M | 57.22M | 138.23M | 34.66M | 40.8M | 45.81M | 40.64M | 31.98M | 30.88M | 30.63M | 32.46M | 18.28M | 23.43M | 22.63M | 20.97M | 17.23M | 16.11M |
| Research and Development Revenue Growth | -7.79% | +15.41% | +5.98% | -12.87% | -19.13% | -13.94% | +15.80% | -15.30% | -35.03% | +20.58% | -32.37% | -3.92% | -4.77% | +44.26% | -5.83% | -1.74% | -19.14% | +12.60% | +1.16% | -21.89% | -3.04% | +56.07% | -17.03% | +9.89% | +12.89% | -58.61% | +298.81% | -15.04% | -10.94% | +12.71% | +27.06% | +3.59% | +0.80% | -5.63% | +77.54% | -21.96% | +3.54% | +7.89% | +21.68% | +6.96% | n/a |